Destiny Pharma PLC Director/PDMR Shareholding (5764Q)
19 Octubre 2023 - 1:00AM
UK Regulatory
TIDMDEST
RNS Number : 5764Q
Destiny Pharma PLC
19 October 2023
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Director/PDMR Shareholding
Brighton, United Kingdom - 19 October 2023 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development and commercialisation of novel medicines to prevent and
treat life threatening infections, announces that it was notified
on 18 October 2023 that on 17 October 2023, Chris Tovey, Chief
Executive Officer of the Company, transferred 30,000 ordinary
shares of 1 pence each in the Company ("Ordinary Shares") to his
wife and two daughters, all PCAs, by way of gift for nil
consideration.
Following the transfer, Chris Tovey's beneficial interest in the
Company remains unchanged at 40,000 Ordinary Shares, representing
0.04 per cent. of the total issued share capital.
For further information, please contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0) 127 370 4440
pressoffice@destinypharma.com
Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)
Geoff Nash / George Dollemore, Corporate Finance
Nigel Birks / Harriet Ward, ECM
+44 (0) 207 220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Powerscourt Group
Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher
Ward
+44 (0) 20 7250 1446
Destiny@powerscourt-group.com
About Destiny Pharma
Destiny Pharma is an innovative, clinical-stage biotechnology
company focused on the development and commercialisation of novel
medicines that can prevent life-threatening infections. The
company's drug development pipeline includes two late stage assets
NTCD-M3, a microbiome-based biotherapeutic for the prevention of C.
difficile infection (CDI) recurrence which is the leading cause of
hospital acquired infection in the US, and XF-73 nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA.
For further information on the Company, please visit www.destinypharma.com
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the company's obligations under Article 17 of MAR.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Chris Tovey
-------------------------------- ------------------------------
2. Reason for the Notification
----------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------- ------------------------------
b) Initial notification/Amendment Initial notification
-------------------------------- ------------------------------
3. Details of the issuer, emission allowance market
participant, auction platform, auctioneer or auction
monitor
----------------------------------------------------------------
a) Name Destiny Pharma plc
-------------------------------- ------------------------------
b) LEI 213800O9WH9Z38EHAC95
-------------------------------- ------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
----------------------------------------------------------------
a) Description of the Ordinary shares of 1 pence
Financial instrument, each
type of instrument
Identification code DEST GB00BDHSP575
-------------------------------- ------------------------------
b) Nature of the transaction Transfer of Ordinary Shares,
by way of gift, to wife and
daughters, Persons Closely
Associated with him, for nil
consideration.
-------------------------------- ------------------------------
c) Price(s) and volume(s) 0 (gift)
30,000 Ordinary Shares
-------------------------------- ------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
-------------------------------- ------------------------------
e) Date of the transaction 17 October 2023
-------------------------------- ------------------------------
f) Place of the transaction Off-Market
-------------------------------- ------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFEEILLTLIV
(END) Dow Jones Newswires
October 19, 2023 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
